[go: up one dir, main page]

NO20045517L - Ny kombinasjon - Google Patents

Ny kombinasjon

Info

Publication number
NO20045517L
NO20045517L NO20045517A NO20045517A NO20045517L NO 20045517 L NO20045517 L NO 20045517L NO 20045517 A NO20045517 A NO 20045517A NO 20045517 A NO20045517 A NO 20045517A NO 20045517 L NO20045517 L NO 20045517L
Authority
NO
Norway
Prior art keywords
inhibitor
new combination
aee
pde5
cgmp
Prior art date
Application number
NO20045517A
Other languages
English (en)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20045517L publication Critical patent/NO20045517L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Kombinasjoner som irmbefatter a) en inhibitor av cykhsk guanosinmonofosfat (cGMP) spesifikk fosfodiesterase type 5 (PDE5) inhibitor og b) en inhibitor av angiotensinomdannende enzym (AeE) er anvendelige for behandling av hypertensjon.
NO20045517A 2002-05-23 2004-12-17 Ny kombinasjon NO20045517L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination
PCT/IB2003/001889 WO2003099194A2 (en) 2002-05-23 2003-05-09 Pharmaceutical combination of pde5 inhibitors with ace inhibitors

Publications (1)

Publication Number Publication Date
NO20045517L true NO20045517L (no) 2004-12-17

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045517A NO20045517L (no) 2002-05-23 2004-12-17 Ny kombinasjon

Country Status (18)

Country Link
EP (1) EP1506015A2 (no)
JP (1) JP2005529927A (no)
KR (1) KR20050004195A (no)
CN (1) CN1655820A (no)
AR (1) AR040090A1 (no)
AU (1) AU2003223071A1 (no)
BR (1) BR0311191A (no)
CA (1) CA2485984A1 (no)
IL (1) IL164975A0 (no)
MX (1) MXPA04010951A (no)
NO (1) NO20045517L (no)
PA (1) PA8574201A1 (no)
PE (1) PE20040514A1 (no)
PL (1) PL374198A1 (no)
RU (1) RU2004133973A (no)
TW (1) TW200407153A (no)
UY (1) UY27816A1 (no)
WO (1) WO2003099194A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
KR20090042863A (ko) 2006-08-24 2009-04-30 서피스 로직스, 인크. 약물동력학적으로 향상된 화합물
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
EP3865120B1 (en) 2013-07-19 2025-06-25 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DK1174431T3 (da) * 1997-11-12 2012-08-20 Bayer Pharma AG 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
JP2003511452A (ja) * 1999-10-11 2003-03-25 ファイザー・インク ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
WO2003099194A3 (en) 2004-06-03
BR0311191A (pt) 2005-03-01
AU2003223071A1 (en) 2003-12-12
MXPA04010951A (es) 2005-06-08
IL164975A0 (en) 2005-12-18
RU2004133973A (ru) 2005-09-10
UY27816A1 (es) 2003-12-31
KR20050004195A (ko) 2005-01-12
TW200407153A (en) 2004-05-16
PL374198A1 (en) 2005-10-03
EP1506015A2 (en) 2005-02-16
PA8574201A1 (es) 2003-12-19
CN1655820A (zh) 2005-08-17
PE20040514A1 (es) 2004-08-24
JP2005529927A (ja) 2005-10-06
WO2003099194A2 (en) 2003-12-04
CA2485984A1 (en) 2003-12-04
AR040090A1 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
NO20045517L (no) Ny kombinasjon
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
EA201000491A1 (ru) Аминометилзамещенные тетрациклиновые соединения
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
SE0203752D0 (sv) New compounds
DE60324805D1 (de) Inhibitoren von tyrosinkinasen
ATE233247T1 (de) Phtalazinonen
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
PL375900A1 (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
IL163777A0 (en) Kinase inhibitors
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
MY133625A (en) Peptide deformylase inhibitors
ATE390425T1 (de) Xanthin-phosphodiesterase-v-hemmer polymorphe
NO20050400L (no) Nytt kombinasjonspreparat
DK1147420T3 (da) Urintrypsininhibitor til diagnosticering af AIDS
AU2003217916A1 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
NO20043173L (no) Benzotiazol- og benzoksazol-4,7-dionderivater og deres anvendelse som CDC25-fosfataseinhibitorer
SE0302361D0 (sv) Inhibering av upptagning av monoamin
TW200509911A (en) Novel combination
DOP2003000645A (es) Nueva combinacion
ATE548037T1 (de) Peptid-deformylase-hemmer
DE60207833D1 (de) Peptiddeformylase-hemmer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application